Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 07 - 13 save search
Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study
Published: 2021-07-13 (Crawled : 22:00) - globenewswire.com
MDGL | $204.65 -6.29% -6.78% 580K
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: -5.62%
treatment phase 3
MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)
Published: 2021-07-13 (Crawled : 16:00) - globenewswire.com
BWAY | $5.03 1.93% 1.89% 26K
|
Health Technology
|
| O: -1.04%
H: 1.33%
C: -0.11%
treatment fda fda clearance depression major depressive disorder
Petros Pharmaceuticals Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment
Published: 2021-07-13 (Crawled : 14:00) - biospace.com/
PTPI | $0.6344 -6.72% -7.1% 180K
|
|
| O: 1.29%
H: 2.39%
C: 1.91%
treatment designation
Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia
Published: 2021-07-13 (Crawled : 13:00) - biospace.com/
MBRX | $4.35 -5.44% 3.37% 7.4K
|
Health Technology
|
| O: 1.12%
H: 3.6%
C: -1.39%
treatment myeloid leukemia europe phase 1 leukemia trial approval phase 2 acute myeloid leukemia
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne
Published: 2021-07-13 (Crawled : 12:15) - ir.hoththerapeutics.com
HOTH | $1.17 -1.68% 1.2% 17K
|
Health Technology
|
| O: 0.67%
H: 0.67%
C: -3.33%
treatment acne potential positive results
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged SarcomasClinical Trial Now Expands to Nine U.S. Trial Sites
Published: 2021-07-13 (Crawled : 12:15) - biospace.com/
SLRX | $0.508 1.4% 1.18% 19K
|
Commercial Services
|
| O: 0.93%
H: 0.0%
C: -4.06%
ewing sarcoma treatment ongoing cancer trial seclidemstat
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
Published: 2021-07-13 (Crawled : 12:00) - biospace.com/
LVTX | $2.74 -8.05% -7.58% 150K
|
|
| O: 0.82%
H: 1.0%
C: -0.91%
treatment phase 1 trial phase 2 phase 3
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Published: 2021-07-13 (Crawled : 12:00) - globenewswire.com
SLRX | $0.508 1.4% 1.18% 19K
|
Commercial Services
|
| O: 0.93%
H: 0.0%
C: -4.06%
ewing sarcoma treatment ongoing cancer trial seclidemstat
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
Published: 2021-07-13 (Crawled : 09:00) - biospace.com/
NRXP 5 d | $3.12 2.3% 1.93% 98K
|
Manufacturing
|
| O: 6.84%
H: 11.25%
C: 5.04%
covid treatment collaboration trial aviptadil
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain
Published: 2021-07-13 (Crawled : 08:00) - globenewswire.com
RARE F | $44.28 -1.84% -1.92% 670K
|
Health Technology
|
| O: -0.16%
H: 2.26%
C: -4.01%
media treatment approval
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
Published: 2021-07-12 (Crawled : 00:01) - globenewswire.com
BIIB | $201.99 4.56% 4.32% 2.7M
|
Health Technology
|
| O: 0.01%
H: 2.33%
C: 0.81%
multiple sclerosis treatment potential collaboration sclerosis license
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.